Teplizumab (Tzield) to Delay Onset of Type 1 Diabetes
Teplizumab (Tzield) to Delay Onset of Type 1 Diabetes
January 9, 2023 (Issue: 1667)
Teplizumab-mzwv (Tzield – Provention Bio), an anti-CD3 monoclonal antibody, has been approved by the
FDA to delay the onset of stage 3 type 1 diabetes
in patients ≥8 years old who have stage 2 type 1
diabetes. It is the first drug to become...more
- KC Herold et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med 2019; 381:603. doi:10.1056/nejmoa1902226
- RA Insel et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 2015; 38:1964. doi:10.2337/dc15-1419
- EK Sims et al. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med 2021; 13:eabc8980. doi:10.1126/scitranslmed.abc8980
- N Sherry et al. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011; 378:487. doi:10.1016/s0140-6736(11)60931-8
- AZ Nourelden et al. Safety and efficacy of teplizumab for treatment of type one diabetes mellitus: a systematic review and meta-analysis. Endocr Metab Immune Disord Drug Targets 2021; 21:1895. doi:10.2174/1871530320999201209222921
- Wholesale acquisition cost according to the manufacturer.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Teplizumab (Tzield) to Delay Onset of Type 1 Diabetes
Article code: 1667c
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
